Anal Cancer Radiotherapy Study (ANCARAD)

University of Oslo (UIO)

Status: Active, not recruiting

Conditions: Anal Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01937780

2012/2274

Details and patient eligibility

About

This is a prospective study of patients receiving radiotherapy or chemoradiotherapy for anal cancer. Treatment effect in terms of survival and local recurrence will be analyzed. The utility of PET-CT and MRI for radiotherapy and for prediction of treatment effect will be investigated. Molecular and genetic markers in tumor and blood will be analyzed for prognostic and predictive effects. Patient-reported outcomes, such as faecal incontinence, sexual dysfunction and quality of life will be assessed. A structured intervention program for management of late effects will be evaluated. Symptom relief of palliative radiotherapy will be investigated. The main purpose of the study is to increase the knowledge of anal cancer treatment, improve treatment results, and improve anal cancer survivor care.

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically verified anal squamous cell carcinoma
• Radiotherapy or chemoradiotherapy planned
• ECOG performance status 0-2
• >= 18 years of age
• Signed informed consent and expected cooperation of the patients for treatment and follow up

Exclusion criteria

• Cognitive or physical condition resulting in inability to sign informed consent or cooperation during treatment